Olfactory Dysfunction in Progressive Supranuclear Palsy

Olfactory Dysfunction in Progressive Supranuclear Palsy

Overview

Olfactory dysfunction represents a significant but often underappreciated feature of progressive supranuclear palsy (PSP).[@postuma2014] While traditionally associated with Parkinson's disease (PD), where it serves as a well-established prodromal marker, olfactory impairment in PSP provides valuable insights into disease pathology, aids in differential diagnosis, and may contribute to understanding the spread of tau pathology through olfactory pathways.

Prevalence and Clinical Features

Prevalence Rates

Olfactory dysfunction in PSP is common but differs in pattern from PD:[@muller2022]

| Measure | PSP | Parkinson's Disease | CBS |
|---------|-----|-------------------|-----|
| Olfactory dysfunction prevalence | 50-70% | 90-95% | 40-60% |
| Severe impairment (anosmia) | 15-25% | 50-70% | 10-20% |
| Mild-moderate impairment | 35-45% | 20-30% | 30-40% |
| Early-stage detection rate | 30-40% | 70-80% | 20-30% |

Clinical Characteristics

The olfactory profile in PSP exhibits several distinctive features:[@defreitas2023]

Pattern of Loss: Mixed olfactory dysfunction affecting both identification and detection thresholds, with relatively preserved odor discrimination compared to PD

Temporal Profile: Often present at diagnosis, may precede motor symptoms in some cases

Progression: Generally stable or slowly progressive, less dramatic decline than PD

Symmetry: No significant lateralization differences

Pathophysiological Mechanisms

Neuroanatomical Correlates

...

Olfactory Dysfunction in Progressive Supranuclear Palsy

Overview

Olfactory dysfunction represents a significant but often underappreciated feature of progressive supranuclear palsy (PSP).[@postuma2014] While traditionally associated with Parkinson's disease (PD), where it serves as a well-established prodromal marker, olfactory impairment in PSP provides valuable insights into disease pathology, aids in differential diagnosis, and may contribute to understanding the spread of tau pathology through olfactory pathways.

Prevalence and Clinical Features

Prevalence Rates

Olfactory dysfunction in PSP is common but differs in pattern from PD:[@muller2022]

| Measure | PSP | Parkinson's Disease | CBS |
|---------|-----|-------------------|-----|
| Olfactory dysfunction prevalence | 50-70% | 90-95% | 40-60% |
| Severe impairment (anosmia) | 15-25% | 50-70% | 10-20% |
| Mild-moderate impairment | 35-45% | 20-30% | 30-40% |
| Early-stage detection rate | 30-40% | 70-80% | 20-30% |

Clinical Characteristics

The olfactory profile in PSP exhibits several distinctive features:[@defreitas2023]

Pattern of Loss: Mixed olfactory dysfunction affecting both identification and detection thresholds, with relatively preserved odor discrimination compared to PD

Temporal Profile: Often present at diagnosis, may precede motor symptoms in some cases

Progression: Generally stable or slowly progressive, less dramatic decline than PD

Symmetry: No significant lateralization differences

Pathophysiological Mechanisms

Neuroanatomical Correlates

The olfactory dysfunction in PSP stems from tau pathology affecting multiple components of the olfactory system:[@becker2021]

Primary Olfactory Structures

• Olfactory bulb: Variable involvement with neurofibrillary tangles in mitral and tufted cells
• Anterior olfactory nucleus: Tau-positive neurons with reduced counts
• Olfactory tract: Degeneration of myelinated fibers

Secondary Structures

• Orbitofrontal cortex: Primary olfactory cortex involvement
• Piriform cortex: Essential for odor discrimination
• Anterior commissure: Transcallosal olfactory connections
• Amygdala: Emotional processing of odors

Tau Pathology Distribution

Autopsy studies reveal tau pathology in olfactory regions:

• Olfactory bulb: Neurofibrillary tangles in 40-60% of PSP cases
• Anterior olfactory nucleus: Nearly universal involvement
• Piriform cortex: Moderate to severe pathology in most cases
• Entorhinal cortex: Early and severe involvement (Braak staging)

Relationship to Disease Subtypes

Olfactory dysfunction varies across PSP phenotypes:

• Richardson syndrome (PSP-RS): Most consistent olfactory impairment (50-70%)
• PSP-Parkinsonism (PSP-P): Similar rates to PSP-RS
• PSP-Pure Akinesia with Gait Freezing (PSP-PAGF): Often preserved olfaction
• Corticobasal syndrome (CBS): Variable, depending on tau burden

Olfactory Bulb Involvement in PSP

Anatomical Considerations

The olfactory bulb represents the primary relay station for odor information, and its involvement in PSP provides critical insights into disease progression:

Cellular Pathology

The olfactory bulb in PSP demonstrates characteristic tau pathology affecting multiple neuronal populations:

• Mitral cells: Primary projection neurons showing neurofibrillary tangles (NFTs) in approximately 40-60% of cases
• Tufted cells: Secondary projection neurons with comparable tau burden
• Granule cells: Interneurons with lesser but significant involvement
• Periglomerular cells: Early involvement in some cases

Glial Pathology

Beyond neuronal involvement, glial cells contribute to olfactory bulb dysfunction:

• Oligodendrocytes: Tau-positive coiled bodies along myelinated fibers
• Astrocytes: Tau pathology in astrocytic processes
• Microglia: Activated microglia associated with tau deposits

Braak Staging and Olfactory Bulb

The progression of tau pathology in PSP follows patterns described by Braak staging, with the olfactory bulb representing an early stage:

| Stage | Olfactory Bulb Involvement | Clinical Correlation |
|-------|---------------------------|----------------------|
| Stage 0-1 | No involvement | Presymptomatic |
| Stage 2 | Mild involvement, anterior olfactory nucleus | Mild olfactory changes |
| Stage 3 | Moderate involvement, mitral cells affected | Overt olfactory dysfunction |
| Stage 4-5 | Severe involvement, global atrophy | Significant impairment |
| Stage 6 | Near-complete degeneration | Severe anosmia |

Functional Consequences

Olfactory bulb pathology produces measurable functional deficits:

• Reduced olfactory discrimination: Inability to distinguish between similar odors
• Elevated detection thresholds: Requires higher odor concentrations for perception
• Impaired odor memory: Difficulty associating smells with past experiences
• Altered odor perception: Parosmia (distorted smell perception) in some cases

Imaging Correlates

Structural and functional imaging reveals olfactory bulb changes:

• Volumetric MRI: Reduced olfactory bulb volume in PSP vs. controls
• Diffusion tensor imaging: Increased mean diffusivity in olfactory tracts
• PET metabolism: Hypometabolism in primary olfactory cortex

Comparison with Parkinson's Disease Olfactory Loss

Epidemiological Comparison

Both PSP and PD demonstrate olfactory dysfunction, but important distinctions exist:

| Feature | PSP | Parkinson's Disease |
|--------|-----|-------------------|
| Prevalence | 50-70% | 90-95% |
| Severity | Mild-moderate | Severe |
| Age of onset | Similar | Similar |
| Disease duration effect | Less pronounced | More pronounced |
| Sex distribution | Equal | Slight male predominance |

Mechanistic Differences

The underlying mechanisms differ substantially between these conditions:

PSP (Tau-Mediated)

• Primary pathology: 4R-tau aggregation in neurons and glia
• Propagation pattern: Retrograde degeneration from brainstem
• Olfactory structures affected: Primary and secondary olfactory regions
• Neurotransmitter involvement: Multiple including GABA and glutamate

PD (Synuclein-Mediated)

• Primary pathology: Alpha-synuclein (α-syn) aggregation in neurons
• Propagation pattern: Braak staging - spreads from olfactory bulb and enteric nervous system
• Olfactory structures affected: Primarily olfactory bulb and anterior olfactory nucleus
• Neurotransmitter involvement: Dopaminergic and cholinergic deficits

Clinical Pattern Differences

The olfactory dysfunction profile differs between PSP and PD:

Detection Threshold

• PD: Markedly elevated thresholds, especially for pleasant odors
• PSP: Moderately elevated thresholds, less selective

Identification

• PD: Severely impaired identification ability
• PSP: Moderately impaired, with better preservation

Discrimination

• PD: Severely impaired odor discrimination
• PSP: Relatively preserved discrimination abilities

Temporal Pattern

• PD: Progressive decline with disease duration
• PSP: More stable, less progressive impairment

Prodromal Utility

The timing of olfactory dysfunction relative to motor symptoms differs:

• PD: Often predates motor symptoms by 5-10 years
• PSP: Variable timing, less reliable prodromal marker
• Combined utility: Olfactory testing helps differentiate when combined with other markers

Tau Pathology in Olfactory Regions

Molecular Mechanisms

Tau Aggregation in Olfactory Neurons

The 4-repeat tau isoform (4R-tau) characteristic of PSP demonstrates unique aggregation patterns in olfactory regions:

Hyperphosphorylation: Multiple kinases contribute to tau phosphorylation in olfactory neurons

Oligomer formation: Soluble tau oligomers precede insoluble aggregate formation

Fibril propagation: Tau fibrils spread transneuronally through olfactory pathways

Cellular toxicity: Both loss-of-function and gain-of-toxic-function mechanisms

Key Kinases Implicated

• GSK-3β: Constitutively active in olfactory bulb neurons
• CDK5: Activity regulated by p35/p39
• MAPK family: ERK1/2 activation in tau phosphorylation

Regional Vulnerability

Different olfactory regions show varying susceptibility to tau pathology:

High Vulnerability Regions

• Anterior olfactory nucleus: Nearly 100% involvement in PSP
• Piriform cortex: 80-90% involvement
• Entorhinal cortex: 70-80% involvement (critical memory interface)

Moderate Vulnerability Regions

• Olfactory tubercle: 50-60% involvement
• Orbitofrontal cortex: 40-50% involvement
• Amygdala: 30-40% involvement

Lower Vulnerability Regions

• Primary olfactory cortex: Variable involvement
• Olfactory bulb: 40-60% involvement

Propagation Mechanisms

The spread of tau pathology through olfactory pathways follows multiple potential mechanisms:

Transneuronal Spread

• Synaptic connections: Tau travels along established neural circuits
• Olfactory tract: Direct pathway from bulb to cortex
• Lateral olfactory tract: Connections to amygdala and hypothalamus

Extracellular Propagation

• Tau secretion: Neuronal release of tau species
• Exosomal transport: Tau within extracellular vesicles
• Direct extracellular spread: Tau peptides in interstitial space

Relationship to Clinical Phenotypes

The distribution of olfactory tau pathology correlates with clinical presentations:

Richardson Syndrome

• Widespread olfactory region involvement
• Correlation with UPSIT scores
• Predicts rapid disease progression

PSP-Parkinsonism

• Similar but less severe involvement
• Greater asymmetry in some cases

PSP-PAGF

• Relative preservation of olfactory regions
• Explains preserved olfactory function

Therapeutic Implications

Understanding olfactory tau pathology informs therapeutic strategies:

Targeting Olfactory Regions

• Intranasal delivery: Direct access to olfactory regions
• Olfactory bulb targeting: Potential for early intervention
• Anti-tau therapies: May benefit olfactory function

Biomarker Development

• CSF tau levels: Correlate with olfactory burden
• Olfactory testing: Non-invasive biomarker readouts
• Imaging markers: Tau PET in olfactory regions

Diagnostic Utility

Differential Diagnosis

Olfactory testing assists in differentiating PSP from other parkinsonian syndromes:

| Condition | Typical Olfactory Function | Utility |
|-----------|---------------------------|---------|
| Parkinson's disease | Severely impaired | High |
| PSP | Moderately impaired | Moderate |
| CBS | Variable | Moderate |
| MSA | Typically preserved | High |
| CBD | Variable | Low-moderate |

Scoring System for Differential Diagnosis

A proposed olfactory scoring system for atypical parkinsonism:

• Normal olfaction → More likely MSA
• Mild-moderate impairment → Compatible with PSP or CBS
• Severe impairment → Suggests PD, unlikely PSP

Diagnostic Algorithm for Differential Diagnosis

Integrating olfactory testing with clinical assessment enhances diagnostic accuracy:

Step 1: Initial Olfactory Assessment

Administer UPSIT or Sniffin' Sticks test

Calculate composite score (TDI)

Categorize: normosmia, mild, moderate, severe dysfunction

Step 2: Pattern Analysis

| Pattern | Likely Diagnosis | Confidence |
|---------|------------------|-------------|
| Severe impairment (TDI < 16) | PD | High |
| Moderate impairment (TDI 16-25) | PSP or CBS | Moderate |
| Mild impairment (TDI 25-30) | Early PSP/CBS | Low |
| Normal olfaction (TDI > 30) | MSA | High |

Step 3: Integration with Clinical Features

Combine olfactory findings with:

• Motor examination: Vertical gaze palsy → increases PSP probability
• Autonomic testing: Orthostatic hypotension → increases MSA probability
• Cognitive profile: Frontal/executive dysfunction → increases PSP probability
• MRI findings: Midbrain atrophy → increases PSP probability

Quantitative Diagnostic Thresholds

| UPSIT Score | Interpretation | Sensitivity for PSP | Specificity vs. PD |
|-------------|---------------|---------------------|-------------------|
| ≥35 | Normal | - | - |
| 30-34 | Mild dysfunction | 65% | 70% |
| 25-29 | Moderate dysfunction | 75% | 55% |
| <25 | Severe dysfunction | 40% | 90% |

Diagnostic Potential for Differential Diagnosis

Olfactory testing provides valuable discriminatory power for differential diagnosis:

PSP vs. PD

The most important distinction in clinical practice:

• Severe olfactory loss strongly favors PD over PSP
• Moderate impairment with vertical gaze palsy favors PSP
• Combined with other markers improves accuracy to >85%

PSP vs. MSA

Key distinguishing feature:

• Preserved olfaction strongly favors MSA (sensitivity 75-85%)
• Impaired olfaction in PSP helps exclude MSA
• Different pathological basis: MSA involves less olfactory tau

PSP vs. CBS

Overlapping but distinguishable:

• CBS with PSP pathology: Similar olfactory profile to PSP
• CBS with AD pathology: More severe impairment
• Asymmetric onset may predict CBS over PSP

Utility in Clinical Practice

Olfactory testing offers several practical advantages:

• Non-invasive: Simple psychophysical testing
• Cost-effective: Minimal equipment required
• Time-efficient: 10-15 minutes for comprehensive testing
• Objective: Quantifiable scores for monitoring

Integration with Biomarker Panel

Olfactory measures function as part of a comprehensive biomarker panel:

| Biomarker Category | PSP Signature | Clinical Utility |
|-------------------|--------------|------------------|
| Olfactory | Moderate dysfunction | Moderate |
| Neuroimaging | Midbrain atrophy | High |
| CSF biomarkers | Elevated 4R-tau | Moderate |
| Clinical markers | Vertical gaze palsy | High |
| Genetic | MAPT mutations | Moderate |

Prodromal Detection

While less robust than in PD, olfactory testing may identify early PSP:

• Sensitivity in prodromal PSP: 30-40%
• Specificity: 70-80% compared to healthy controls
• Combined with other markers: Improves predictive value

Clinical Assessment

Testing Methods

Psychophysical Testing

• University of Pennsylvania Smell Identification Test (UPSIT): 40-item scratch-and-sniff test
• Sniffin' Sticks Test: 16-item screening test
• Threshold-Discrimination-Identification (TDI): Comprehensive assessment

Electrophysiological Testing

• Olfactory event-related potentials (OERP): Late-latency responses
• Electro-olfactogram (EOG): Peripheral receptor activity

Imaging Correlates

• MRI: Volumetric analysis of olfactory structures
• PET: Metabolic changes in piriform cortex

Clinical Interpretation

| TDI Score | Interpretation | PSP Probability |
|-----------|---------------|-----------------|
| >30 | Normosmia | Low |
| 25-30 | Mild dysfunction | Low-moderate |
| 16-25 | Moderate dysfunction | Moderate |
| <16 | Severe dysfunction | Low (suggests PD) |

Comparison with Other Parkinsonian Syndromes

PSP vs. Parkinson's Disease

While both conditions involve olfactory dysfunction, key differences exist:

• Severity: PD typically shows more severe impairment
• Pattern: PD shows greater impairment in identification vs. detection
• Progression: More rapid decline in PD
• Pathology: Different underlying mechanisms (synuclein vs. tau)

PSP vs. Multiple System Atrophy

The distinction is particularly relevant:

• MSA: Generally preserved olfaction
• PSP: Moderate impairment in majority
• Sensitivity: 75-85% for MSA vs. PSP differentiation

PSP vs. Corticobasal Syndrome

Overlap exists but differences emerge:

• CBS with PSP pathology: Similar to PSP
• CBS with AD pathology: More severe impairment
• Asymmetric presentations: May affect olfactory laterality

Clinical Implications

Quality of Life Impact

Olfactory dysfunction affects multiple domains:

• Food enjoyment: Reduced appetite and nutrition
• Safety: Inability to detect smoke, gas leaks
• Social interaction: Reduced quality of life
• Mood: Association with depression

Management Strategies

Environmental Modifications

• Visual cues for food identification
• Safety systems for hazard detection
• Enhanced food presentation (color, texture)

Safety Recommendations

• Smoke detectors in all rooms
• Natural gas detectors
• Regular food expiration checks

Nutritional Considerations

• Enhanced flavoring of foods
• Texture-modified diets when needed
• Weight monitoring

Research Directions

Biomarker Potential

Olfactory measures are being investigated as potential biomarkers:

• Disease progression: Correlation with clinical decline
• Therapeutic trials: Outcome measures
• Pathological correlation: Tau burden relationship

Mechanistic Model: Tau Spread via Olfactory Pathways

Advanced Imaging Biomarkers

High-Resolution Olfactory Bulb MRI

Advances in MRI technology enable detailed visualization of olfactory structures:

• 3D T1-weighted imaging: Volumetric analysis of olfactory bulb
• T2-weighted sequences: Detection of olfactory tract pathology
• Diffusion weighted imaging: Microstructural integrity assessment
• Quantitative metrics: Thickness, volume, signal intensity

PET Ligand Development

Emerging tau PET ligands offer insights into olfactory region involvement:

• 18F-AV-1451 (Flortaucipir): Binds to tau tangles in olfactory regions
• 11C-PBB3: Multiple tau isoform binding
• Regional quantification: Olfactory bulb, piriform cortex, entorhinal cortex

Combined Multimodal Assessment

Integration of multiple imaging modalities enhances diagnostic accuracy:

| Modality | Information Gained | PSP-Specific Findings |
|----------|-------------------|----------------------|
| MRI volumetry | Structural atrophy | Reduced olfactory bulb volume |
| DTI | White matter integrity | Increased FA in olfactory tract |
| PET metabolism | Functional activity | Hypometabolism in piriform cortex |
| PET tau | Tau deposition | Tau binding in olfactory regions |

Imaging Developments

• High-resolution MRI: Olfactory bulb volumetry
• Diffusion tensor imaging: Olfactory tract integrity
• PET ligands: Tau deposition in olfactory regions

Longitudinal Studies

Ongoing research examines:

• Prodromal identification: Olfactory changes pre-diagnosis
• Progression markers: Predictive value over time
• Treatment response: Olfactory outcomes in trials

Cross-References

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [PSP Clinical Variants](/diseases/psp-clinical-variants)
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)
• [Tau Pathology in PSP](/mechanisms/psp-neuropathology)
• [Differential Diagnosis of Parkinsonian Syndromes](/mechanisms/parkinsonism-differential-diagnosis)
• [Olfactory Dysfunction in Parkinson's Disease](/mechanisms/parkinson-olfactory-dysfunction)
• [MAPT Gene and Tauopathies](/genes/mapt)